Over the past decade, the incidence of overweight and obesity has increased dramatically worldwide. According to a WHO survey, in 2022 there were approximately 1 billion people who were obese or overweight, representing a threefold increase compared with 1975 . Obesity is considered a major risk factor for metabolic syndrome (including insulin resistance, dyslipidemia, and hypertension), which subsequently leads to an increased risk of cardiovascular and cerebrovascular events, as well as higher
Conditions
Interventions
after receiving GLP1 patients will be measured plasma aldosterone and renin level
Experimental Other
Sponsors
Faculty of Medicine, Chiang Mai University
Eligibility
Sex/Gender
All
Age
20 Years to 90 Years
Inclusion criteria
Inclusion criteria: 1. type 2 diabetes mellitus patients with obesity (BMI > 25), Body fat percentage > 25% in men and > 32% in women, as measured by bioelectrical impedance analysis, waist circumference > 90 cm in male and > 80 cm in female, 2. A treatment plan involving a once-weekly injectable GLP-1 receptor agonist 3. Age more than 20 years old 4. Receiving care at the outpatient internal medicine clinic, Maharaj Nakorn Chiang Mai Hospital, between September 1, 2025, and September 30, 2026
Exclusion criteria
Exclusion criteria: Presence of other causes of overweight or obesity (secondary obesity), such as Cushing syndrome, hypothyroidism, heart failure, or end-stage renal disease requiring dialysis, including both hemodialysis and peritoneal dialysis Patients with contraindications to the use of GLP-1 receptor agonists Inability to tolerate adverse effects or any reason necessitating discontinuation of GLP-1 receptor agonist therapy before completing 3 months of treatment Pregnant women Patients receiving treatment with corticosteroids Patients who are unable to attend scheduled follow-up visits
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To investigate the association between changes in aldosterone and renin levels after treatment with GLP-1 receptor agonists in overweight patients with type 2 diabetes mellitus at 3 months 3 months changes in aldosterone and renin levels | — |
Secondary
| Measure | Time frame |
|---|---|
| waist circumference, body mass index, blood glucose, glycated hemoglobin (HbA1c), blood pressure, body weight, and body fat percentage 3 months associations between aldosterone and renin levels and changes in these parameters | — |
Countries
Thailand
Contacts
Public ContactPitsinee Wangpattanamongkol
Faculty of medicine, Chaing Mai university
Outcome results
None listed